Masters moments: Ian Woosnam wins in 1991 and gets a lift from caddie ‘Wobbly’ | Golf News

first_imgWe continue our look back through the Augusta archives by remembering Ian Woosnam’s dramatic victory at The Masters in 1991. As the countdown continues towards the delayed 2020 Masters, we take you back to 1991 at Augusta National and Ian Woosnam’s maiden major triumph.Woosnam arrived for his fourth Masters appearance ranked second in the world behind defending champion Nick Faldo, and with five top-10 finishes to his name in major championships.The Welshman was five off the pace after an opening-round 72, but he responded with an impressive 62 on day two which got him within two strokes of the halfway leader, and home favourite, Tom Watson. 2:25 Woosnam receives the green jacket from Nick Faldo Woosnam receives the green jacket from Nick Faldo

England: Raheem Sterling and Jordan Henderson out of Nations League clash vs Iceland | Football News

first_imgVisit or the Sky Sports App for all the breaking sports news headlines. You can receive push notifications from the Sky Sports app for the latest news from your favourite sports and you can also follow @SkySportsNews on Twitter to get the latest updates. – Advertisement – Raheem Sterling and Jordan Henderson have been ruled out of England’s Nations League clash with Iceland on Wednesday because of injury.More to follow…- Advertisement –center_img This is an England breaking news story that is being updated and more details will be published shortly. Please refresh this page for the latest updates.Sky Sports brings you live updates as they happen. Get breaking sports news, analysis, exclusive interviews, replays and highlights.Sky Sports is your trusted source for breaking sports news headlines and live updates. Watch live coverage of your favourite sports: Football, F1, Boxing, Cricket, Golf, Tennis, Rugby League, Rugby Union, NFL, Darts, Netball and get the latest transfers news, results, scores and more.- Advertisement –last_img read more

With H1N1 resistance, CDC changes advice on flu drugs

first_imgDec 19, 2008 (CIDRAP News) – Increased resistance to oseltamivir (Tamiflu), the leading influenza drug, has prompted federal health officials to change their advice about flu treatment, saying clinicians for now should consider using zanamivir (Relenza) or a combination of two drugs for patients suspected of having influenza A.The Centers for Disease Control and Prevention (CDC) today said 49 of 50 influenza A/H1N1 viruses tested so far this season have shown resistance to oseltamivir. But all the isolates remained sensitive to zanamivir and to the two older flu drugs, amantadine and rimantadine.H1N1 is one of the three viral types and subtypes included in season flu vaccine; the others are A/H3N2 and B.”When influenza A (H1N1) virus infection or exposure is suspected, zanamivir or a combination of oseltamivir and rimantadine are more appropriate options than oseltamivir,” the CDC said in today’s advisory. “Local influenza surveillance data and laboratory testing can help with physician decision-making regarding the choice of antiviral agents for their patients.”But Dr. Anthony Fiore, a medical epidemiologist in the CDC’s Influenza Division, said rapid flu tests don’t identify the viral subtype, and many areas don’t have good flu surveillance data. “This problem really does complicate deciding what kind of antiviral to use,” he told CIDRAP News.At the same time, he said US flu activity remains low so far this season, and the resistant H1N1 viruses seem no more virulent than susceptible ones. In its weekly surveillance update today, the CDC said 3 states have reported local flu activity, while 36 states have reported only sporadic cases. Another 11 states have reported no flu cases yet.The CDC said vaccination should continue as the primary method for preventing the flu, as the oseltamivir-resistant H1N1 viruses are antigenically similar to the H1N1 strain in this year’s vaccine.Resistance emerged last seasonSince January 2006, oseltamivir and zanamivir have been the only antivirals recommended for flu in the United States. At that point the CDC advised clinicians to stop using amantadine and rimantadine, known as the adamantanes, because H3N2 viruses had become highly resistant to them. Today’s interim guidance puts the adamantanes back in the recommendations.Significant H1N1 resistance to oseltamivir emerged in the United States and a number of other northern hemisphere countries during the 2007-08 flu season. Overall, 10.9% of tested H1N1 viruses in this country showed resistance, according to the CDC.But resistance rose to nearly 100% in some southern hemisphere countries, particularly Australia and South Africa, in their 2008 season, said Fiore.The CDC’s new interim recommendations for healthcare providers include the following:Review local or state flu virus surveillance data weekly to determine which types and subtypes are circulating.Consider using rapid tests that can distinguish types A and B. Fiore said some rapid tests can do this, but others can’t.Patients who test positive for type B can be given either oseltamivir or zanamivir if treatment is indicated.If a patient tests positive for type A, zanamivir should be considered if treatment is indicated. Oseltamivir should be used alone only if local surveillance data suggest that circulating viruses are likely to be A/H3N2 or B. A combination of oseltamivir and rimantadine is an acceptable alternative, and may be necessary for patients who can’t take zanamivir, which is taken by inhalation and is not licensed for children younger than 7 years. Amantadine can replace rimantadine if the latter is not available.If a patient tests negative on a rapid flu test, clinicians should still consider treatment, depending on local flu activity and clinical signs and symptoms. (Fiore said rapid tests are not very sensitive and work better in children than adults.) If treatment is indicated, zanamivir or a combination of oseltamivir and rimantadine should be considered.Where available, testing for viral subtypes can guide treatment. For patients with an H3N2 or B virus, either oseltamivir or zanamivir can be used; for an H1N1 infection, zanamivir or the combination of oseltamivir and rimantadine can be used.What pushed the CDC to make the new recommendations, said Fiore, was the high level of resistance in the H1N1 viruses tested, plus the fact that most of the viruses tested so far this season have been H1N1.The latter factor could easily change, he said. “Last season at this time, H1N1 was the most common [subtype], but a month later they were a distant third place. That could happen again. So these are interim guidelines, and one hope we have is that clinicians will recognize that things are a little complicated this year and keep track of the recommendations that come out.”Fiore said polymerase chain reaction (PCR) tests that can identify flu subtypes are now available, but their use is mostly limited to specialty labs, such as state health departments. Once samples arrive at the lab, the tests take a couple of hours. “So if you were going to wait to decide therapy, you’re going to end up with a pretty substantial delay,” he said.Also, he said many areas don’t have good local flu surveillance data. “That advice to look at local data is probably not going to be useful in a lot of areas,” he commented.On the other hand, he noted, “We don’t have much flu activity of any kind right now. . . . And things could continue to evolve and change.”He added, “The fact is that most people don’t get antiviral treatment in the first place. And the resistant viruses are not any more dangerous or virulent, so the person is not going to know if they have resistant flu.”Experts air practical concernsKristine Moore, MD, MPH, medical director of the University of Minnesota Center for Infectious Disease Research and Policy, which publishes CIDRAP News, said she’s not surprised by the sudden spike in antiviral resistance in this year’s circulating H1N1 strain. She said influenza A viruses have a strong tendency to mutate rapidly, and that increasing use of oseltamivir has placed more selective pressure on the virus.The quick emergence of antiviral resistance and the CDC’s revised treatment recommendation have important implications for pandemic flu planning, Moore said. A rapid change affecting treatment could happen in a pandemic influenza strain. “This teaches us not to rely on any one strategy,” she said.William Schaffner, MD, chairman the Department of Preventive Medicine at the Vanderbilt University School of Medicine, told CIDRAP News that healthcare providers expect a little disconcerting news each flu season. “But we got the prize in the Cracker Jack box early this year,” he said.If physicians need to prescribe treatment for some of their patients who have influenza, they’re going to have to get a sense of what strains are circulating in their area, which will be a change for many practitioners.Schaffner advises physicians to use the rapid test to guide treatment. Patients who have the B strain will still benefit from oseltamivir treatment.Though the CDC recommends zanamivir as an option for treating patients who have A strains, Schaffner said many physicians aren’t as familiar with teaching patients how to use the inhaler. “Pharmacists are going to be very helpful,” he said.Some experts questioned if physicians will have enough information about what influenza subtypes are circulating in their area. Kristen Ehresmann, RN, MPH, manager of immunization, tuberculosis, and international health at the Minnesota Department of Health (MDH) in St. Paul, told CIDRAP News that many state public health laboratories have the reagents used to distinguish influenza subtypes.However, she said getting a timely picture of the circulating strains will be a challenge. Though most public health labs easily handle sentinel surveillance samples, they have a more limited ability to process randomly submitted samples.”Every state’s resources are different,” Ehresmann said, adding that the MDH uses a weekly e-mail listserv to update clinicians on the status of circulating influenza strains.Schaffner said he contacted Vanderbilt’s virus lab today and asked if they could start subtyping the influenza A strains and communicating the results to Tennessee’s health department and the general medical community.”This is new for the labs, but there is an urgency for this information,” he said. “Doctors will have to learn how to keep up with information about the circulating strains.”The experts who spoke with CIDRAP News said they were concerned about the nation’s supply of zanamivir, given the CDC’s revised antiviral recommendations. Moore said even if the supply seems adequate, some regions of the country may still experience shortages.However, GlaxoSmithKline, the maker of zanamivir, said today in a press release that it has sufficient supplies to meet the needs of the 2008-09 influenza season and that pharmacies can get the medicine from their wholesalers.Moore and Schaffner both expressed concerns about the combination (oseltamivir and rimantadine) therapy alternative recommended for patients who can’t take zanamivir. “It’s a reasonable recommendation, but its efficacy and safety have never been demonstrated in humans,” Moore said.Added impetus to vaccinateA silver lining in the CDC’s antiviral resistance warnings and treatment recommendations is that they strengthen the rationale for seasonal flu vaccination, the experts said. “These events speak to the value of vaccination and not counting on being able to treat influenza after the fact,” Ehresmann said.Schaffner, who is also president-elect of the National Foundation for Infectious Diseases, said vaccine supplies are abundant this year, and an examination of early viral isolates suggests that the vaccine is a good match with the circulating strains.This year so far looks like a typical flu season, and activity usually peaks in February, he said, “so there’s still time to be protected by getting the vaccine through December and into January.”See also:CDC interim antiviral guidance for 2008-2009CDC weekly flu surveillance updatelast_img read more

On the one hand, he was plastered …

first_imgTo access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletterslast_img

‘Preemployment card ineffective, gimmicky’, CEO participant claims

first_imgHe went on to share how the program worked by buying courses.“The cash went directly to the account of the online platform, mine was Skill Academy by education startup Ruangguru,” he told The Jakarta Post as he also showed the invoice via text message.The program involves as many as 223 training institutions, providing more than 2,000 courses through eight online platforms including Skill Academy, Tokopedia, Bukalapak and Sisnaker.He added that he received an email notification suggesting that he buy another course on Skill Academy to get Rp 100,000 (US$6.70) worth of benefits and a free subscription to Ruangguru. Journalist and entrepreneur Agustinus Edy Kristianto has slammed the government’s flagship preemployment card skill training program for missing the target and serving only as a business gimmick as he tried the program in late April.Edy managed to sign up for cash assistance despite the program objective having shifted from upgrading worker skills and reducing unemployment to supporting laid-off and furloughed workers during the COVID-19 pandemic. As the founder and CEO of online news portal Gressnew, he does not meet the criteria.“The system accepted a shareholder like me. I indicated that I was an entrepreneur. I’m not someone who has lost their job nor a small entrepreneur who has lost customers,” Edy wrote as his Facebook status on Thursday. Read also: Preemployment card management defends program amid criticismThe government has allocated Rp 20 trillion to cover around 5.6 million people in the program. Eligible participants will each receive Rp 1 million to cover online training costs, Rp 2.4 million in incentives for four months that will only be disbursed if a participant has completed a course and Rp 150,000 if they have completed a survey.Many have criticized the government for allocating budgetary funds to online training courses, which experts have slammed as being similar to those available for free on the internet, while the COVID-19 crisis is hitting people hard.Furthermore, Edy said the program let him obtain a certificate without completing the materials first.As he took a journalism course, he also questioned how the certificate on a course titled “writing news like an expert journalist” was not given by a journalism institution accountable for conducting competency tests. The certificate is only signed by the Skill Academy CEO.There are 27 institutions verified by the Press Council to conduct journalism competency tests, the Alliance of Independent Journalist’s (AJI) head of education, ethics and profession, Dandy Koswara, said.“Certificates that are issued by institutions other than those appointed by the Press Council do not reflect the competence of the holder in journalism,” he said.The director of communication, partnership and ecosystem development for the preemployment card program, Panji Ruky, brushed off complaints that the certificate was not meant as a certification of a profession but only as evidence that the participant had completed the course.Panji admitted that the management did not determine a specified standard for courses but they ensured the online trainers had a curriculum and all the infrastructure needed.“We leave the curriculum to the course providers. We give the consumers cash assistance and many options so they have a wide variety of courses to choose from. Let the market put the spotlight on the good quality providers,” Panji told the Post.Read also: Sewing masks to silky pudding making: Training available with preemployment cardSkill Academy claimed it had developed its courses with experts in the respective fields, Ruangguru spokesperson Sekar Krisnauli said in a written statement.She also explained that the platform issued two kinds of certificates, one for passing the exam above the passing grade and the other for completing the course material. Therefore, a participant could get a certificate for passing an exam without completing the material first, as in Edy’s case.As for Edy’s successful enrollment in the program despite him being an entrepreneur, Panji said the program was open to anyone aged 18 years or above who is currently not attending university, including entrepreneurs.He further mentioned there were two categories of applicants. The first group comprises those whom the government has recorded as COVID-19 affected workers, and who are the management’s priority. He claimed the majority of applicants were in the first group, without specifying the number.The second group, he added, were members of the public yet to be identified. Panji said applicants must declare that they have either been laid-off or economically affected by indicating if they are currently experiencing a lower income or fewer customers.Edy, however, denied there was such a process during registration.“Yes, I said I was an entrepreneur who has been affected by COVID-19 because it’s true. However, I’m not severely affected and there’s no further question asking the details of how I am affected,” Edy said.Topics :last_img read more

Foreign arrivals plunge 60% in first half of 2020

first_imgThe number of foreign tourists arriving on Indonesia’s shores plummeted 59.96 percent to 3.09 million in the first half of the year as the COVID-19 pandemic brought tourism to its knees, Statistics Indonesia (BPS) reported Monday.In June, foreign visitor numbers were down 88.82 percent year-on-year (yoy) to around 160,300. The month-to-month figures also fell 2.06 percent, marking a return to a downward trend after a brief uptick in May that suggested a sign of recovery.“The recovery may take quite a long time,” Suhariyanto, the head of BPS, said in a virtual presser on Monday.Despite having yet to bring the coronavirus under control, Indonesia is seeking to speed up the recovery of tourism by reopening Bali, a world-renowned tourist destination. Domestic travelers could visit Bali from July 31 and international visitors will be permitted starting from Sept. 11.With more than 82,000 visitors, Timor Leste accounted for around half of all foreign arrivals in June, followed by Malaysia with around 62,760 visitors and China with more than 2,000 visitors.“We are still seeing a negative year-on-year change in all foreign tourist [arrivals],” said Suhariyanto.“There was an uptick, but things are still far from normal, so we still need to work hard to attract foreign tourists to Indonesia. The key is the end of the pandemic and compliance with health protocols.”With most domestic and international travel having ceased, the occupancy rate of star hotels across Indonesia remained low at 19.70 percent in June, a drop of 32.57 percentage points from June of 2019.“The occupancy rate is not only about foreign tourists, but also about domestic tourists and business trips,” said the BPS head.The pandemic has cost the hotel and restaurant industry almost Rp 70 trillion (US$4.76 billion) and the aviation and tour industry Rp 15 trillion, according to data compiled last month by the Indonesian Hotel and Restaurant Association (PHRI).Most entry points to Indonesia continued to record declines in foreign arrivals in June, with a few exceptions like Soekarno-Hatta International Airport in Banten, which saw a 130.13 percent monthly increase, and Juanda International Airport in East Java, which saw a 708.33 percent monthly increase, following the relaxation of large-scale social restrictions.Read also: ASEAN hotel associations endorse travel bubbleTopics :last_img read more

Lehmans scheme insured in £675m deal with Rothesay after TPR action

first_imgA settlement between the pension scheme and Lehman Brothers International Europe (LBIE) funded the deal.After the US bank collapsed in 2008, prompting administration for its international operations, the UK pension fund entered assessment for The Pension Protection Fund (PPF).However, the £2bn scheme was left with a significant deficit, leading TPR – supported by trustees and the PPF –to launch legal challenges, demanding funding from subsidiary organisations undergoing administration.In August last year, the case was finally settled.The LBIE agreed to fund the scheme to secure a full insurance bulk annuity buyout, with members now also receiving back pay on restricted benefits, and the PPF avoiding the burden.Gamester expressed his gratitude to the scheme’s advisers and LBIE for securing member benefits in full.“Since the bankruptcy of Lehman Brothers in 2008, the trustees have been striving to secure the pension benefits promised to members of the scheme,” he said.This is the first major public bulk annuity deal in 2015 after last year saw a record £12bn of pensions liabilities absorbed by insurers.It is estimated there has been around £2.5bn of bulk annuity deals so far in 2015, with two buy-in deals worth more than £500m in addition to the Lehmans scheme.This year has been noticeably quieter than 2014, which saw £4.3bn written in Q1 and £2.5bn in Q2 last year.Legal & General (L&G) – which dominated the 2014 market, with a 45% market share – today announced £655m of new premiums for Q1 2015, £2.4bn down on last year after it took on £3bn from the ICI Pension Fund.Rothesay wrote no business in Q1 on the build-up to the Lehmans deal but has now surpassed its performance for the first half of 2014 where it wrote only £556m.It wrote a total of £1.7bn in 2014, as it struggled to keep pace with rivals L&G, Pension Insurance Corporation (PIC).PIC is also seeing a quieter 2015, with expectations of new Q1 premiums around £100m compared with £148m in 2014, finishing the year on £2.5bn, some £1.2bn down on 2013.Research from L&G showed nearly half of UK pension funds are set to use insurance products to underpin liabilities by 2020, as more than one-third of schemes aim for self-sufficiency using a buy-in contract.Analysis by consultancy LCP showed that, if half of UK schemes insured half their liabilities by 2020, the bulk annuity market would require annual capacity of £25bn – double that seen in 2014. Bulk annuity provider Rothesay Life has insured the UK Lehman Brothers Pension Scheme after The Pensions Regulator (TPR) secured funding from subsidiary groups for the abandoned defined benefit (DB) scheme.The £675m (€916m) deal, the largest in 2015, has seen the pension scheme transfer all risks to the insurer, with an end to restricted benefits after legal wrangling between TPR and the US bank’s administrators.Rothesay is owned by US bank Goldman Sachs, Singaporean sovereign wealth fund GIC, asset manager Blackstone and Massachusetts Mutual Life Insurance.Peter Gamester, chair of trustees for the scheme, said the deal secured full benefits for members – something the board had been working for since the bank’s insolvency in 2008.last_img read more

Bavarian foundation seeks equity fund managers via IPE Quest

first_imgA Bavarian-based foundation has, via a consultant, tendered two equity mandates of up to €10m apiece using IPE Quest.One of the mandates is for long/short equities, and the other is for a market-neutral approach. Both can be global, regional or country-focused.According to search QN-2296 and search QN-2297, the consultant’s client wants to select one to two asset managers for each mandate, which could be split into tranches of €2m-€4m.The managers should in each case offer non-leveraged UCITs funds “in euro hedged and possibly distributing institutional share classes”. The process should be active and the benchmark should be the HFRX Equity Hedge Index.Applicants should have at least €250m of assets under management for the asset class and a minimum track record of two years, although three is preferred.The minimum tracking error expected is 0.5% for each mandate, with a maximum of 5% for the long/short equities mandate and 4% for the market neutral mandate.Interested parties have until 27 April to apply.The IPE news team is unable to answer any further questions about IPE Quest tender notices to protect the interests of clients conducting the search. To obtain information directly from IPE Quest, please contact Jayna Vishram on +44 (0) 20 7261 4630 or email read more

I will not leave you orphans

first_imgFaithLifestyleLocalNews I will not leave you orphans by: – May 30, 2011 By: Father Henry CharlesPhoto credit: flickr.comSeveral years ago, I was in the middle of a sermon dealing with relationships and freedom, and I was emphasizing the fact that people are not possessions, that nobody can belong to anybody else, and so on. A husband in the congregation turned to his wife, to whom he was exceptionally devoted, and said (as she told me herself later): “He could say what he want, but you belong to me.”I have often recalled the effect the occasion had on me. It made me laugh, but it has never left my memory.  What the husband was giving voice to is not something uniquely proper to husbands. Few human needs are as great as the need to have someone who ‘belongs’ to us and to whom we ourselves ‘belong.’  Our orphanages are full of children who belong to nobody, and there’s little doubt that that awareness has a powerful effect on how they see themselves and how they grow up.But an orphanage is not the only place or situation where we experience the reality of being un-anchored, for that it what being orphaned is all about. The person has so security in any one anywhere. It’s the feeling of abandonment, and it affects people other than those who are literally orphans.It happens all the time. Divorce leaves children – and spouses – abandoned. Lovers walk out on lovers. Companies downsize and employees are put on the breadline.  Even situations that begin with friends and well-wishers crowding around to support and befriend, the funeral of someone widely loved, for instance. Soon the crowds become thin, and life goes on, as it must. But that offers no consolation to the bereaved. They can’t blame anybody, but they feel abandoned all the same, and the reason is obvious: no one in this world wants to go it alone.      The disciples of Jesus felt much the same thing with his leaving them. They were not simply men who had ‘followed’ him. The years they had spent together had made them more than a community; they were a family. And the head of the family was now taking off. He is saying good-bye. To go where? As Thomas said: “Lord we do not know where you are going,” so how could you expect us to have any idea where you’ll be…They had other preoccupations of course: what about the plans we had ourselves? The hopes we had of sharing in your ascendancy? What about all of that?  With you gone, where does that leave us?  They felt abandoned, suddenly unanchored, as I said, and the feeling was hard.The feelings of the disciples were of course proper to them, but they are not unique feelings. Many of us know feelings like theirs ourselves. The bottom suddenly falls out with something unexpected; suddenly the ground beneath us has shifted, leaving on the bank of nowhere.Jesus does not tell them: don’t worry, friends, tomorrow will be a brighter day. He offers them no such breezy optimism. What he promises is his powerful presence. That will accompany them through all the terrors of abandonment. Trust me, he says. You will never be alone.That promised presence, St. John tells us, is the Holy Spirit, our advocate, comforter, and friend. We never lose, though we often do not feel, the radical nearness of this comfort, just as Jesus himself was never deprived of in Gethsemane and on the Cross.  That’s the reason that our hearts should not be troubled, why trust should not leave us, in the midst of fears about the future in any experience of abandonment. Share Sharing is caring! Tweetcenter_img 1019 Views   one comment Share Sharelast_img read more

Tim Foley

first_imgTimothy Paul John Foley age 64 of Batesville, Indiana passed away on Thursday, June 25, 2020.  The son of Doris and Paul Foley was born on December 21, 1955 in Batesville.Tim worked for Batesville Tool & Die as a machine operator for 20 years. He was quite the fan of NASCAR.  He enjoyed watching old movies and listening to 60’s and 70’s music. Tim liked being outdoors and when he was younger was always out fishing.   He will be dearly missed by his family and many friends.Tim is survived by his brothers Steven Foley and Rick Foley; sister, Glenda (John) Riehle and sister-in-law, Tina Foley.In addition to his parents, he was preceded in death by his brother, Pat Foley.Visitation will be Thursday, July 2, 2020 from 1-3pm followed by a 3pm funeral service, all at Meyers Funeral Home in Batesville.  Rev. Shawn Crisman officiating.Memorials may be given to MMH Hospice c/o the funeral home.Continuing with COVID-19 precautions, all attending will be asked to follow proper social distancing protocol. Masks are encouraged. If you are not feeling well, or if you have compromised immune system, you are encouraged to stay home.You are welcome to leave a message at on Tim’s obituary page for the family in the online guestbook.last_img read more